Pulmatrix reports FY2023 net loss narrowed; cash runway extended to Q1 2026 on Cipla amendment

Pulmatrix, Inc.

Cash and equivalents $19.2M at Dec 31, 2023; projected runway into Q1 2026.
Net loss $14.1M ($3.87/share) for FY2023, improved from $18.8M ($5.46/share) in FY2022.
Revenue $7.3M, up $1.2M YoY due to higher PUR1900 activity under Cipla agreement.
Cipla amendment: wind-down of PUR1900 Phase 2b; Pulmatrix gets 2% royalty on net sales, no further development cost.
R&D spend fell $2.7M to $15.5M; G&A fell $0.3M to $6.5M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pulmatrix, Inc. reported the year ended December 31, 2023 results: revenue $7.3 million.

Period: the year ended December 31, 2023
Revenue: $7.3 million
Result: reported results

Exact text from the filing

Revenues increased $1.2 million to $7.3 million for the year ended December 31, 2023, compared to $6.1 million for the year ended December 31, 2022.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Pulmatrix, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-011627

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.